Mirati Therapeutics Inc (DELISTED) (MRTX:DL)
58.70
0.00 (0.00%)
USD |
NASDAQ |
Jan 23, 16:00
Mirati Therapeutics Cash from Financing (Quarterly): 334.70M for Sept. 30, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 334.70M |
| June 30, 2023 | 3.843M |
| March 31, 2023 | 1.727M |
| December 31, 2022 | 5.92M |
| September 30, 2022 | 157.10M |
| June 30, 2022 | 1.392M |
| March 31, 2022 | 2.527M |
| December 31, 2021 | 479.28M |
| September 30, 2021 | 8.232M |
| June 30, 2021 | 7.823M |
| March 31, 2021 | 9.885M |
| December 31, 2020 | 889.89M |
| September 30, 2020 | 12.35M |
| June 30, 2020 | 9.273M |
| March 31, 2020 | 339.20M |
| December 31, 2019 | 3.473M |
| September 30, 2019 | 1.072M |
| June 30, 2019 | 221.88M |
| March 31, 2019 | 111.60M |
| December 31, 2018 | 0.462M |
| September 30, 2018 | 2.157M |
| June 30, 2018 | 132.34M |
| March 31, 2018 | 5.89M |
| December 31, 2017 | 89.64M |
| September 30, 2017 | 2.149M |
| Date | Value |
|---|---|
| June 30, 2017 | 0.071M |
| March 31, 2017 | 66.82M |
| December 31, 2016 | 0.06M |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.266M |
| March 31, 2016 | 2.326M |
| December 31, 2015 | 0.355M |
| September 30, 2015 | 95.07M |
| June 30, 2015 | 0.335M |
| March 31, 2015 | 48.61M |
| December 31, 2014 | 0.351M |
| September 30, 2014 | 0.10M |
| June 30, 2014 | 0.174M |
| March 31, 2014 | 0.262M |
| December 31, 2013 | 54.74M |
| September 30, 2013 | 0.022M |
| June 30, 2013 | 0.00 |
| March 31, 2013 | 0.00 |
| December 31, 2012 | 24.83M |
| September 30, 2012 | 0.00 |
| June 30, 2012 | -0.013M |
| March 31, 2012 | -0.003M |
| December 31, 2011 | 0.5008M |
| September 30, 2011 | -2.221M |
| June 30, 2011 | 32.77M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
1.072M
Minimum
Sep 2019
889.89M
Maximum
Dec 2020
138.31M
Average
8.752M
Median
Cash from Financing (Quarterly) Benchmarks
| Bristol-Myers Squibb Co | 14.64B |
| Karuna Therapeutics Inc (DELISTED) | 19.87M |
| Puma Biotechnology Inc | 0.00 |
| NovaBay Pharmaceuticals Inc | -0.597M |
| Palatin Technologies Inc | 9.136M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -143.71M |
| Cash from Investing (Quarterly) | -62.19M |
| Free Cash Flow | -595.93M |
| Free Cash Flow Per Share (Quarterly) | -2.212 |
| Free Cash Flow to Equity (Quarterly) | -143.75M |
| Free Cash Flow to Firm (Quarterly) | -143.75M |